Glioblastoma Clinical Trials in Nashville, Tennessee
7 recruitingNashville, Tennessee
Showing 1–7 of 7 trials
Recruiting
Phase 2
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled317 locationsNCT06325683
Recruiting
Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Pancreatic CancerLung CancerColon Cancer+3 more
RasCal Therapeutics, Inc.134 enrolled3 locationsNCT04678648
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled41 locationsNCT06860594
Recruiting
Phase 1Phase 2
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 2
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Glioblastoma
ImmunityBio, Inc.34 enrolled4 locationsNCT06061809
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Breast CancerOvarian CancerEndometrial Cancer+40 more
Massive Bio, Inc.50,000 enrolled68 locationsNCT03452774
Recruiting
Phase 1Phase 2
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Glioblastoma Multiforme
VBI Vaccines Inc.98 enrolled12 locationsNCT03382977